MedTrace Logo

Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

NCT04977674 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-03-02

No results posted yet for this study

Summary

The overarching aim of this research is to determine the acute effects of ketamine on brain glutamate, functional connectivity and cerebral blood flow in treatment-resistant depression, explore whether the effects are attenuated by the opioid receptor antagonist naltrexone and relate these findings to antidepressant response.

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

DRUG

Naltrexone

Pre-treatment with naltrexone 45 min before the ketamine infusion.

DRUG

Placebo

Pre-treatment with placebo 45 min before the ketamine infusion.

DRUG

Ketamine

Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2023-02-13
Completion
2023-02-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04977674 on ClinicalTrials.gov